Table.
Trial* | Type of injury | No of patients | Treatment
|
Length of follow up | Mortality reported | Allocation concealment | |
---|---|---|---|---|---|---|---|
Colloid | Crystalloid | ||||||
Lowe et alw1-w3 | Trauma | 171 | 50 g albumin/200 ml Ringer’s lactate | Ringer’s lactate | 5 days | Yes | 1 |
Modigw4 w5 | Trauma | 31 | Dextran-70 in Ringer’s acetate | Ringer’s acetate | To definitive reconstructive surgery | Yes | 1 |
Nagy et alw6 | Trauma | 41 | Pentastarch in 0.9% NaCl | Ringer’s lactate | Unspecified | Yes | 1 |
Younes et alw7 | Trauma | 70 | 6% dextran-70 in 7.5% NaCl | 7.5% NaCl | To discharge | Yes | 3 |
Vassar et alw8 | Trauma | 174 | 6% dextran-70 in 7.5% NaCl | 7.5% NaCl | To hospital discharge | Yes | 3 |
Vassar et alw9 | Trauma | 149 | 6% or 12% dextran-70 in 7.5% NaCl | 7.5% NaCl | To hospital discharge | Yes | 3 |
Evans et alw10 | Trauma | 25 | Haemacell in Ringer’s lactate | Ringer’s lactate | Unspecified | No | 2 |
Skillman et alw11 | Surgery | 16 | 25% concentrated salt-poor albumin; 1 g/kg and 5% albumin in saline | Ringer’s lactate with 5% dextrose | 1 day | No | 2 |
Boutros et alw12 | Surgery | 24 | Albumin in 5% dextrose | 5% dextrose in lactated Ringer’s; 5% dextrose in 0.45% NaCl | To 48 hours postoperative | Yes | 2 |
Virgilio et alw13 | Surgery | 29 | 5% albumin in Ringer’s lactate | Ringer’s lactate | 2½ weeks | Yes | 2 |
Grundmann et alw14 w15 | Surgery | 20 | Human albumin and crystalloid (details not reported) | Crystalloid (details not reported) | Unspecified | Yes | 1 |
Karanko et alw16 w17 | Surgery | 36 | 6% dextran-70 in 0.9% NaCl or in 5% glucose | Ringer’s acetate gluconate | 2 weeks | Yes | 2 |
Ley et alw18 | Surgery | 21 | 6% hetastarch and 5% plasma protein fraction | 0.9% NaCl | To discharge | No | 2 |
Prein et alw19 | Surgery | 18 | 10% hydroxyethylstarch in 154 mmol/l NaCl and plasma protein solution; 20% human albumin solution | Ringer’s lactate | Unspecified | No | 2 |
Dawidson et alw20 | Surgery | 20 | 3% dextran-60 in Ringer’s lactate | Ringer’s lactate | To discharge | Yes | 2 |
Hartmann et alw21 | Surgery | 29 | Dextran-70 in NaCl with 2.5% glucose | NaCl with 2.5% glucose | 7 days | No | 2 |
Eleftheriadis et alw22 | Surgery | 91 | 6% hydroxyethylstarch | Ringer’s solution and 3.5% gelatine solution | Unspecified | No | 2 |
Tollosfrud et alw23 | Surgery | 40 | Haemacell; dextran-70; albumin 40 mg/ml in saline | Ringer’s acetate | To 48 hours | Yes | 3 |
Wahba et alw24 | Surgery | 22 | Haemacell in Ringer’s lactate | Ringer’s lactate | To discharge | Yes | 2 |
Bocanegra et alw25 | Burns | 153 | Plasma with saline; whole blood supplemented with 5% glucose | Isotonic saline | To 60 hours, then unspecified | Yes | 1 |
Hall et alw26 | Burns | 172 | 6% dextran-70 in 0.9% NaCl | Ringer’s lactate | To 5 years | Yes | 1 |
Jelenko et alw27-w30 | Burns | 12 | Albumin in hypertonic saline (240 mEq Na+, 120 mEq Cl−, 120 mEq lactate, 3.5 torr/l colloid) | Hypertonic saline (240 mEq Na+, 120 mEq Cl−, 120 mEq lactate) | To end of resuscitation | Yes | 2 |
Goodwin et alw31 | Burns | 79 | 2.5% albumin in Ringer’s lactate | Ringer’s lactate | To discharge | Yes | 2 |
Rackow et alw32-w34 | Septic and hypovolaemic shock | 26 | 6% hydroxyethylstarch; 5% albumin | 0.9% NaCl | To discharge | Yes | 2 |
Metildi et alw35 | Adult respiratory distress syndrome | 46 | 50% albumin salt-poor serum in Ringer’s lactate | Ringer’s lactate | To discharge | Yes | 2 |
Pockaj et alw36 | Vascular leak syndrome | 107 | 5% albumin in 154 mEq/l NaCl | 0.9% normal saline with 154 mEq/l NaCl | Unspecified | No | 2 |
For list of references see longer version of article on our website www.bmj.com.